Do not initiate in patients w/ active infection, including clinically important localized infection. Use w/ caution in patients w/ chronic infection or history of recurrent infection. Evaluate for TB risk factors & test for latent infection prior to & during therapy. Monitor HBV carriers for signs of HBV reactivation. Opportunistic & invasive fungal infections, malignancies (eg, lymphoma, acute & chronic leukemia). Non-lymphoma malignancy, colon dysplasia/carcinoma, melanoma. Immunosuppression. Discontinue if new/worsening symptoms of CHF appear. Central or peripheral nervous system demyelinating disorders & significant cytopenias. Discontinue if patient develops symptoms of a lupus-like syndrome. Consider discontinuation in case of confirmed significant hematologic abnormalities. Concomitant w/ abatacept, anakinra, other biological therapeutics & live vaccines. Increased risk of infection when switching between biological therapeutics (biological DMARDs). Monitor for infections patients who require surgery while on therapy. May have a minor influence on the ability to drive & use machines. Pregnancy & lactation. Elderly. Childn <18 yr.